Business Description
Natco Pharma Ltd
ISIN : INE987B01026
Share Class Description:
NSE:NATCOPHARM: Ordinary SharesTotal Employee Number:
4,955Compare
Compare
Traded in other countries / regions
524816.India Index Membership
NIFTY 500 IPO Date
1995-12-27Description
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.02 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 0.41 | |||||
Interest Coverage | 33.51 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.53 | |||||
Beneish M-Score | -1.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.5 | |||||
3-Year EBITDA Growth Rate | 19.5 | |||||
3-Year EPS without NRI Growth Rate | 26.4 | |||||
3-Year FCF Growth Rate | 29.7 | |||||
3-Year Book Growth Rate | 24.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.88 | |||||
9-Day RSI | 38.3 | |||||
14-Day RSI | 42.11 | |||||
3-1 Month Momentum % | -18.26 | |||||
6-1 Month Momentum % | 7.41 | |||||
12-1 Month Momentum % | -10.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.01 | |||||
Quick Ratio | 2.47 | |||||
Cash Ratio | 1.71 | |||||
Days Inventory | 439.15 | |||||
Days Sales Outstanding | 114.76 | |||||
Days Payable | 210.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.54 | |||||
Dividend Payout Ratio | 0.06 | |||||
3-Year Dividend Growth Rate | -3.1 | |||||
Forward Dividend Yield % | 0.71 | |||||
5-Year Yield-on-Cost % | 0.56 | |||||
3-Year Average Share Buyback Ratio | 0.6 | |||||
Shareholder Yield % | -0.94 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.07 | |||||
Operating Margin % | 30.16 | |||||
Net Margin % | 34.78 | |||||
EBITDA Margin % | 42.52 | |||||
FCF Margin % | 33.77 | |||||
OCF Margin % | 43.36 | |||||
ROE % | 16.7 | |||||
ROA % | 14.12 | |||||
ROIC % | 17.96 | |||||
3-Year ROIIC % | 13.33 | |||||
ROC (Joel Greenblatt) % | 36.8 | |||||
ROCE % | 17.75 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.63 | |||||
Forward PE Ratio | 22.05 | |||||
PE Ratio without NRI | 11.63 | |||||
Shiller PE Ratio | 16.86 | |||||
Price-to-Owner-Earnings | 8.31 | |||||
PEG Ratio | 0.31 | |||||
PS Ratio | 4.04 | |||||
PB Ratio | 1.79 | |||||
Price-to-Tangible-Book | 1.84 | |||||
Price-to-Free-Cash-Flow | 11.97 | |||||
Price-to-Operating-Cash-Flow | 9.33 | |||||
EV-to-EBIT | 9.38 | |||||
EV-to-EBITDA | 8.27 | |||||
EV-to-Forward-EBITDA | 9.96 | |||||
EV-to-Revenue | 3.52 | |||||
EV-to-Forward-Revenue | 4.6 | |||||
EV-to-FCF | 10.41 | |||||
Price-to-GF-Value | 1 | |||||
Price-to-Projected-FCF | 1.05 | |||||
Price-to-DCF (Earnings Based) | 0.6 | |||||
Price-to-DCF (FCF Based) | 0.5 | |||||
Price-to-Median-PS-Value | 0.69 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.46 | |||||
Price-to-Graham-Number | 0.97 | |||||
| Price-to-Net-Current-Asset-Value | 5.16 | |||||
| Price-to-Net-Cash | 16.2 | |||||
Earnings Yield (Greenblatt) % | 10.66 | |||||
FCF Yield % | 8.35 | |||||
Forward Rate of Return (Yacktman) % | 23.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Natco Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 40,783 | ||
| EPS (TTM) (₹) | 79.2 | ||
| Beta | 1.1511 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.39 | ||
| Volatility % | 31.3 | ||
| 14-Day RSI | 42.11 | ||
| 14-Day ATR (₹) | 28.111819 | ||
| 20-Day SMA (₹) | 949.55 | ||
| 12-1 Month Momentum % | -10.56 | ||
| 52-Week Range (₹) | 789 - 1226.8 | ||
| Shares Outstanding (Mil) | 179.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Natco Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Natco Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-13 16:30 | In 112 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 111 days | ||
| General meeting for 2026 | 2026-09-25 11:00 | In 63 days | ||
| Annual report for 2026 | 2026-08-28 | In 34 days | ||
| First quarter earnings conference call for 2027 | 2026-08-13 11:00 | In 20 days | ||
| First quarter earnings results for 2027 | 2026-08-13 | In 19 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-29 16:30 | 1,175.80 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-29 | 1,175.80 (+0.00%) | ||
| INR 1.500000 Cash Dividend | 2026-02-18 | 884.70 (-0.31%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-12 16:00 | 850.80 (+0.24%) |
Show
Entries
Natco Pharma Ltd Frequently Asked Questions
What is Natco Pharma Ltd(NSE:NATCOPHARM)'s stock price today?
The current price of NSE:NATCOPHARM is ₹921.45. The 52 week high of NSE:NATCOPHARM is ₹1226.80 and 52 week low is ₹789.00.
When is next earnings date of Natco Pharma Ltd(NSE:NATCOPHARM)?
The next earnings date of Natco Pharma Ltd(NSE:NATCOPHARM) is 2026-08-13 Est..
Does Natco Pharma Ltd(NSE:NATCOPHARM) pay dividends? If so, how much?
The Dividend Yield %  of Natco Pharma Ltd(NSE:NATCOPHARM) is 0.54% (As of Today), Highest Dividend Payout Ratio of Natco Pharma Ltd(NSE:NATCOPHARM) was 0.55. The lowest was 0.06. And the median was 0.18. The  Forward Dividend Yield % of Natco Pharma Ltd(NSE:NATCOPHARM) is 0.71%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Breckenridge launches Pomalidomide Capsules, strengthening its oncology portfolio | 2026-03-02 |
Articles on Natco Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers